Voyager Therapeutics (VYGR) Free Cash Flow (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Free Cash Flow data on file, last reported at -$33.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 13.28% year-over-year to -$33.4 million; the trailing twelve-month figure through Mar 2026 stood at -$127.8 million (down 10.02% YoY), and the FY2025 full-year result was -$132.9 million, down 605.72% from the prior year.
• Free Cash Flow retreated to -$33.4 million in Q1 2026, from -$28.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $123.1 million in Q1 2023 to a low of -$38.6 million in Q1 2025.
• A 5-year average of -$7.4 million and a median of -$23.5 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow surged 259.83% in 2023 and tumbled 9072.75% in 2024, its largest moves.
• Tracing VYGR's Free Cash Flow over 5 years: stood at -$13.2 million in 2022, then tumbled by 86.04% to -$24.5 million in 2023, then soared by 40.1% to -$14.7 million in 2024, then sank by 95.59% to -$28.7 million in 2025, then decreased by 16.41% to -$33.4 million in 2026.
• Business Quant data shows VYGR's Free Cash Flow at -$33.4 million in Q1 2026, -$28.7 million in Q4 2025, and -$31.3 million in Q3 2025.